

pFUSE-hIgG3*01-Fc1

Plasmid designed for the construction of Fc-Fusion proteins

Catalog # pfuse-hg301fc1

For research use only

Version 20K04-MMv35

PRODUCT INFORMATION

Content:

- 20 µg of pFUSE-hIgG3*01-Fc1 plasmid provided as lyophilized DNA
- 1 ml of Zeocin™ (100 mg/ml)

Storage and Stability:

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C and is stable 3 months.
- Resuspended DNA should be stored at -20°C and is stable up to 1 year.
- Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pFUSE-Fc is a family of plasmid developed to facilitate the construction of Fc-fusion proteins by fusing the effector region of a protein to the Fc region of an immunoglobulin G (IgG).

pFUSE-Fc plasmids yield high levels of Fc-fusion proteins. The level of expression is usually in the µg/mL range. They can be transfected in a variety of mammalian cells, including myeloma cell lines, CHO cells, monkey COS cells and human embryonic kidney (HEK)293 cells, cells that are commonly used in protein purification systems.

pFUSE-Fc plasmids allow the secretion of Fc-Fusion proteins. As Fc-Fusion proteins are secreted, they can be easily detected in the supernatant of pFUSE-Fc-transfected cells by SDS-PAGE. Furthermore, functional domains can be identified by immunoblotting and ligand blotting.

Fc-Fusion proteins can be easily purified by single-step protein A or protein G affinity chromatography.

InvivoGen provides pFUSE-Fc vectors featuring Fc regions from different species and isotypes. In humans, there are four isotypes: IgG1, IgG2, IgG3 and IgG4. The Fc region mediates effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). IgG isoforms exert different levels of effector functions increasing in the order of IgG4<IgG2<IgG1≤IgG3.

PLASMID FEATURES

- **hIgG3-Fc (allele 1):** The Fc region comprises the CH2 and CH3 domains of the IgG heavy chain and the hinge region. The hinge serves as a flexible spacer between the two parts of the Fc-fusion protein, allowing each part of the molecule to function independently. Human IgG3 displays high ADCC and CDC.
- **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter¹ and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat². The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.
- **MCS:** The multiple cloning site contains several restriction sites that are compatible with many other enzymes, thus facilitating cloning.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA³.
- **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **CMV enh / hFerL prom:** This composite promoter combines the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of the human ferritin light chain gene. This ubiquitous promoter drives the expression of the Zeocin™-resistance gene in mammalian cells.
- **EM2KC** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*. EM2KC is located within an intron and is spliced out in mammalian cells.
- **Zeo:** Resistance to Zeocin™ is conferred by the *Sh ble* gene from *Streptoalloteichus hindustanus*. The same resistance gene confers selection in both mammalian cells and *E. coli*.
- **BGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription⁴.

References:

1. Kim DW *et al.* 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. 91(2):217-23.
2. Takebe Y. *et al.* 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol. 8(1):466-72.
3. Carswell S. & Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol Cell Biol. 9(10):4248-58.
4. Yu J. & Russell JE. 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol. 21(17):5879-88.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-3480
E-mail: info@invivogen.com

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20 °C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or in other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.

RELATED PRODUCTS

Product	Catalog Code
Zeocin™	ant-zn-1

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



PvuI (7)
SgfI (6)
 1 GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGAGAGCGCACATCGCCACAGTCCCGGAGAAGTTGGGGGAGGGGTCGGCAATTGAACGGGTGCCTA
 101 GAGAAGGTGGCGCGGGTAAACTGGAAAGTGATGTCGTGTAAGTGGTCCGCCTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCC

Psp1406I (203) **HindIII (245)** **PvuII (239)** **Bsu36I (291)**
 201 GTGAACGTTCTTTTTTCGCAACGGGTTTGGCCGACAGACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCTTACCGCGCCCGCCGCTACCTGAGGGCC
 301 GCCATCCACGCGGTTGAGTGCCTTCTGCCGCTCCCGCTGTGGTGCCTCCTGAAGTGCCTCCGCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACC
 401 GGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGCTCTCCACGCTTTCCTGACCTGCTTGTCTCAACTCTACGTCTTTGTTTCGTTT

EcoRI (558) **KasI (535)** **AgeI (552)** **SgrAI (551)** **EcoRV (564)** **XhoI (569)** **NcoI (577)** **BglIII (585)**
 501 TCTGTTCTGCGCGGTTACAGATCCAAGCTGTGACCGCGGCTACCTGAGATCACCGTGAATTCGATATCTCGAGCACCATGTTAGATCTGACACACCT
 1 D T P

BbsI (648) **Bsu36I (699)**
 601 CCCCCTGCCAAGGTGCCAGCACCTGAAGTCTGGGAGGACCGTCAAGTCTTCTTCCCCAAAACCAAGGATACCTTATGATTTCCCGGACCC
 4 P P C P R C P A P E L L G G P S V F L F P P K P K D T L M I S R T

BbrPI (707) **BbsI (735)**
 701 CTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAAGTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAA
 3 P E V T C V V V D V S H E D P E V Q F K W Y V D G V E V H N A K T K

SacII (801)
 801 GCCCGGGAGGAGCAGTACAACAGCACGTTCCGTGGTGCAGCGTCTCACCGTCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTCAAGGTC
 7 P R E E Q Y N S T F R V V S V L T V L H Q D W L N G K E Y K C K V

BsrGI (973) **XmaI (991)**
 901 TCCAACAAAGCCCTCCAGCCCCATCGAGAAAACCATCTCCAAAACCAAGGACAGCCCGAGAACCACAGGTGTACACCCTGCCCCATCCCGGGAGG
 10 S N K A L P A P I E K T I S K T K G Q P R E P Q V Y T L P P S R E
 1001 AGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTACCCAGCGACATCGCCGTGGAGTGGGAGAGCAGCGGGCAGCCGGAGAACA
 13 E M T K N Q V S L T C L V K G F Y P S D I A V E W E S S G Q P E N N

XmnI (1190)
 1101 CTACAACACCAGCCTCCATGCTGACTCCGACGGCTCCTTCTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACATCTTC
 17 Y N T T P P M L D S D G S F F L Y S K L T V D K S R W Q Q G N I F

NsiI (1212) **NheI (1277)** **MscI (1283)**
 1201 TCATGCTCCGTGATGCGATGAGGCTTCGACAACCGCTTACGCGAGAAGAGCCTTCCCTGTCTCCGGGTAATGAGTGTAGCTGGCCAGACATGATAAG
 20 S C S V M H E A L H N R F T Q K S L S L S P G K
 1301 ATACATTGATGAGTTGGACAAACCACAACCTAGAATGCAGTGAATAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATA

HpaI (1415)
 1401 AGCTGCAATAAACAGTTAAACAACAACAAATTGCATTCAATTTATGTTTCAGGTTCAAGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAACCTCTACA

AseI (1513) **XmnI (1511)**
 1501 AATGTGGTATGGAATTAATCTAAATACAGCATAGCAAAACTTAACTCCTCAATCAAGCCTCTACTTGAATCCTTTCTGAGGGATGAATAAGGCATA
 1601 GGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTCTTTCATGGAGTTAAGATATAGTGTATTTTCCAAGGTTTGAAGTACCT

SspI (1754) **Swal (1768)**
 1701 CTTCAATTTCTTTATGTTTTAAATGCACTGACCTCCACATTCCCTTTTTAGTAAAAATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATG
 1801 TTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTATAATATCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGA

ApaLI (1953) **DraIII (1947)** **EagI (1967)**
 1901 CAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCTGCTCCTCTGCCACAAAGTGCACGAGTTGCCGGCCGGGTGCGCGAGGGCGAACTCCCGCCCC
 125 D Q E E A V F H V C N G A P D R L A F E R G W
 2001 ACGGCTGCTCGCCGATCTCGGTGATGGCCGGCCGGAGGCGTCCCGGAAGTTCGTGGACACGACTCCGACCCTCGCGTACAGCTCGTCCAGGCGCGC
 10 P Q E G I E T M A P G S A D R F N T S V V E S W E A Y L E D L G R

SgrAI (2183)
 2101 CACCACACCCAGGCCAGGGTGTGTTCGGGACCACCTGGTCTGACCGCGCTGATGAACAGGGTACGTCGTCCCGGACCACACCGGCGAAGTCTGTC
 6 V W V W A L T N D P V V Q D Q V A S I F L T V D D R V V G A F D D

XmaI (2210) **BsrBI (2246)** **BssHII (2262)** **MscI (2297)**
 2201 TCCACGAAGTCCCGGGAGAACCCGAGCCGGTCCGAGAACTCAGCCGCTCCGGCGAGCTCGCGCGGTGAGCACCAGGAAACGGCACTGGTCAACTTGG
 3 E V F D R S F G L R D T W F E V A G A V D R A T L V P V A S T L K A

AseI (2397)
 2301 CCATGATGGCTCCTCctgtcaggagaggaagagaagaagggttagtacaattgtCTATAGTGAGTTGTATTATACTATGCAGATATACTATGCCAATGATT
 1 M

PstI (2416)
 2401 AATTGTCAAACCTAGGGCTGCAgggttcatagtccacttttctgcactgcccactctctgccaccctttccaggcatagacagtcaagtactc

2501 A A A C T C A C A G G A G G G A A A G G C A G A A G C T T G A G A C A G A C C C G C G G G A C C G C C A A C T G C G A G G G G A C T G G C T A G G G C G G C T T C T T T T A T G G T G C G C C G G
HindIII (2524) SacII (2539)
2601 C C C T C G G A G G C A G G G C G C T C G G G A G G C C T A G C G G C C A A T C T G C G G T G G C A G G A G G C G G G G C C G A A G G C C G T G C C T G A C C A A T C C G G A G C A C A T A G G A G T
StuI (2624) BspEI (2682)
2701 C T C A G C C C C C G C C C C A A A G C A A G G G G A A G T C A C G C G C C T G T A G C G C C A G C G T G T T G T G A A A T G G G G G C T T G G G G G G T T G G G G C C C T G A C T A G T C A A A A
SpeI (2789)
Bsp120I (2781)
2801 C A A A C T C C C A T T G A C G T C A A T G G G G T G G A G A C T T G G A A A T C C C C G T G A G T C A A A C C G C T A T C C A C G C C A T T G A T G T A C T G C C A A A A C C G C A T C A T C A T G
SnaBI (2917)
2901 G T A A T A G C G A T G A C T A A T A C G T A G A T G T A C T G C C A A G T A G G A A A G T C C C A T A A G G T C A T G T A C T G G G C A T A A T G C C A G G C G G G C A T T T A C C G T C A T T G A
NdeI (3022)
3001 C G T C A A T A G G G G G C T A C T T G G C A T A T G A T A C A C T T G A T G T A C T G C C A A G T G G G C A G T T T A C C G T A A A T A C T C C A C C A T T G A C G T C A A T G G A A A G T C C C
3101 T A T T G G C G T T A C T A T G G G A A C A T A C G T C A T T A T T G A C G T C A A T G G G C G G G G T C G T T G G G C G G T C A G C A G G C G G G C A T T T A C C G T A A G T T A T G T A A C G
PacI (3208)
PstI (3201)
SdaI (3200) BspLU11I (3218)
3201 C C T G C A G G T T A A T T A A G A A C A T G T G A G C A A A A G C C A G C A A A A G G C C A G G A A C C G T A A A A A G G C C G C G T T G C T G G C G T T T T C C A T A G G C T C C G C C C C C C
3301 T G A C G A G C A T C A C A A A A A T C G A C G C T C A A G T C A G A G G T G G C G A A A C C C G A C A G G A C T A T A A A G A T A C C A G G C G T T T C C C C T G G A A G C T C C C T C G T G C G C
3401 T C T C T G T T C C G A C C T G C C G T T A C C G G A T A C C T G T C C G C T T T C T C C T T C G G A A G C G T G G C G T T T C T A T A G C T C A C G C T G T A G G T A T C T C A G T T
ApaLI (3532)
3501 C G G T G T A G G T C G T T C G C T C C A A G C T G G G C T G T G T G C A C G A A C C C C C G T T C A G C C C G A C C G C T G C G C T T A T C C G G T A A C T A T C G T C T T G A G T C C A A C C C
3601 G G T A A G A C A C G A C T T A T C G C C A C T G G C A G C A G C C A C T G G T A A C A G G A T T A G C A G A G C G A G G T A T G T A G G C G G T G C T A C A G A G T T C T T G A A G T G G T G G C C T
3701 A A C T A C G G C T A C A C T A G A A G A A C A G T A T T T G G T A T C T G C G C T C T G C T G A A G C C A G T T A C T T C G G A A A A A G A G T T G G T A G C T C T T G A T C C G G C A A A C A A A
3801 C C A C C G C T G G T A G C G G T G G T T T T T T T G T T T G C A A G C A G C A G A T T A C G C G C A G A A A A A A A G A T C T C A A G A A G A T C C T T T G A T C T T T T C T A C G G G G T C T G A
EagI (3968)
PacI (3948) SmaI (3957) NotI (3967)
3901 C G C T C A G T G G A A C G A A A A C T C A C G T T A A G G G A T T T T G G T C A T G G C T A G T T A A T T A A C A T T T A A A T C A G C G G C C G C A A T A A A A T A T C T T T A T T T T C A T T A C
4001 A T C T G T G T T G T T T T T T G T G T G A A T C G T A A C T A A C A T A C G C T C C A T C A A A A C A A A A C G A A A C A A A A C A A A C T A G C A A A A T A G G C T G T C C C C A G T G C
4101 A A G T G C A G G T G C C A G A A C A T T T C T A T C G A A